prikaz prve stranice dokumenta Hormonska terapija karcinoma prostate
  Download
PDF 786.62 KB
master's thesis
Hormonska terapija karcinoma prostate
2019. urn:nbn:hr:184:930643
Pedišić, Mirta
University of Rijeka
Faculty of Medicine
Department of Urology

Cite this document

Pedišić, M. (2019). Hormonska terapija karcinoma prostate (Master's thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:930643

Pedišić, Mirta. "Hormonska terapija karcinoma prostate." Master's thesis, University of Rijeka, Faculty of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:184:930643

Pedišić, Mirta. "Hormonska terapija karcinoma prostate." Master's thesis, University of Rijeka, Faculty of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:184:930643

Pedišić, M. (2019). 'Hormonska terapija karcinoma prostate', Master's thesis, University of Rijeka, Faculty of Medicine, accessed 17 April 2024, https://urn.nsk.hr/urn:nbn:hr:184:930643

Pedišić M. Hormonska terapija karcinoma prostate [Master's thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2019 [cited 2024 April 17] Available at: https://urn.nsk.hr/urn:nbn:hr:184:930643

M. Pedišić, "Hormonska terapija karcinoma prostate", Master's thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:184:930643

Please login to the repository to save this object to your list.
Metadata
TitleHormonska terapija karcinoma prostate
Title (english)Hormonal therapy of the prostate cancer
AuthorMirta Pedišić
MentorDean Markić (mentor)
Committee memberRomano Oguić (predsjednik povjerenstva)
Committee memberJosip Španjol (član povjerenstva)
Committee memberStanislav Sotošek (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of Urology)
Rijeka
Defense date and country2019-07-12, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Urology
Abstract
Karcinom prostate u većini razvijenih zemalja za muškarace starije životne dobi predstavlja najčešći oblik karcinoma te drugi uzrok smrti od malignih oboljenja. Kod otkrivanja bolesti bitnu ulogu imaju digitorektalni pregled te antigen specifičan za prostatu. Konačna dijagnoza se donosi na temelju patohistološkog nalaza biopsije prostate vođene transrektalnim ultrazvukom. U pacijenata niskog rizika i s dužim očekivanim preživljenjem preporuka je aktivnog nadzora. Aktivno liječenje koje podrazumijeva radikalnu prostatektomiju ili radikalnu radioterapiju provodi se u lokaliziranoj bolesti. Kod lokalno uznapredovalog karcinoma, a kod kojega se neće provesti lokalni tretman, terapija izbora je oprezno čekanje kao alternativa hormonskoj terapiji. Hormonska terapija adrenogenom deprivacijom pokazala je poboljšanje sveukupnog preživljenja kod lokalno uznapredovale bolesti u kombinaciji s radioterapijom, kod ranog stadija s nepovoljnom prognozom, kod metastatske bolesti u kombinaciji s radikalnom prostatektomijom te kod povratka bolesti. Usmjerena je na snižavanje razine androgena u cirkulaciji ili blokiranje vezanja androgena na androgeni receptor. Četiri su temeljna oblika androgene deprivacije, a uključuju primjenu ablacije androgenih izvora, antiandrogene, inhibiciju LHRH i/ili LH te inhibiciju sinteze androgena. Nuspojave hormonske terapije uključuju osteoporozu, valove vrućine, gubitak libida, promjene kognitivnih funkcija, promjene vanjskog izgleda, ginekomastiju i anemiju. Nažalost, nakon nekog vremena gotovi svi karcinomi prostate prelaze u oblik rezistentan na androgenu manipualciju.
Abstract (english)
In majority of developed countries prostate cancer is for older males the most common type of cancer and the second cause of death from malignant diseases. Digital rectal exam and prostate specific antigens have an important role in detecting the disease. The final diagnosis is based on pathohistological findings of prostate biopsy guided by transrectal ultrasound. In patients with low risk and longer expected survival, active surveillance is recommended. Active treatment involving radical prostatectomy or radical radiotherapy is performed in a localized disease. In locally advanced disease, where local treatment is not being performed, therapy of choice is watchfull waiting as an alternative to hormonal therapy. Hormonal therapy with deprivation of androgen has shown an improved overall survival in locally advanced disease when combined with radiotherapy, in early stage with unfavourable prognosis, in metastatic disease when combined with radical prostatectomy and at relapse of disease. It is focused on lowering androgen levels in circulation or blocking binding of androgen to the androgen receptor. There are four fundamental forms of androgen deprivation, including ablation of androgen sources, antiandrogens, inhibition of LHRH and/or LH and inhibition of androgen synthesis. Side effects of hormonal therapy include osteoporosis, hot flushes, loss of libido, changes in cognitive functions, changes in external appearance, gynecomastia and anemia. Unfortunately, after a while, all prostate cancers progress into a form that is resistant to androgen manipulation.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:930643
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2019-12-12 18:47:48